Amneal Pharmaceuticals Inc (NYSE:AMRX) major shareholder International Ltd Fosun bought 1,642,300 shares of the firm’s stock in a transaction that occurred on Monday, August 5th. The stock was purchased at an average cost of $3.04 per share, for a total transaction of $4,992,592.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of AMRX stock opened at $2.40 on Friday. The stock has a market cap of $852.41 million, a PE ratio of 2.53, a price-to-earnings-growth ratio of 0.35 and a beta of 1.41. The company’s fifty day moving average price is $4.30 and its 200-day moving average price is $9.69. Amneal Pharmaceuticals Inc has a 12 month low of $2.38 and a 12 month high of $24.48. The company has a current ratio of 2.17, a quick ratio of 1.41 and a debt-to-equity ratio of 3.66.
Amneal Pharmaceuticals (NYSE:AMRX) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.14 by ($0.05). The firm had revenue of $404.60 million during the quarter, compared to the consensus estimate of $420.12 million. Amneal Pharmaceuticals had a positive return on equity of 28.20% and a negative net margin of 3.65%. The business’s revenue for the quarter was down 12.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.24 EPS. On average, sell-side analysts forecast that Amneal Pharmaceuticals Inc will post 0.51 earnings per share for the current fiscal year.
Several analysts recently weighed in on the stock. Zacks Investment Research cut shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th. ValuEngine upgraded shares of Amneal Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, May 7th. Royal Bank of Canada cut shares of Amneal Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price target for the company from $11.00 to $6.00 in a report on Thursday, July 11th. Piper Jaffray Companies upgraded shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $11.00 price target on the stock in a report on Monday, July 8th. Finally, Svb Leerink upgraded shares of Amneal Pharmaceuticals from a “market perform” rating to an “outperform” rating and cut their price target for the company from $11.00 to $5.00 in a report on Monday, July 22nd. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $12.13.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Read More: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.